BR112023016183A2 - Conjugados de peptídeo de penetração celular e métodos de uso dos mesmos - Google Patents
Conjugados de peptídeo de penetração celular e métodos de uso dos mesmosInfo
- Publication number
- BR112023016183A2 BR112023016183A2 BR112023016183A BR112023016183A BR112023016183A2 BR 112023016183 A2 BR112023016183 A2 BR 112023016183A2 BR 112023016183 A BR112023016183 A BR 112023016183A BR 112023016183 A BR112023016183 A BR 112023016183A BR 112023016183 A2 BR112023016183 A2 BR 112023016183A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- acid residues
- methods
- peptide
- oligonucleotide
- Prior art date
Links
- 239000000863 peptide conjugate Substances 0.000 title abstract 2
- 230000035515 penetration Effects 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract 1
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
conjugados de peptídeo de penetração celular e métodos de uso dos mesmos. são descritos conjugados de um oligonucleotídeo e um peptídeo unido covalentemente ou ligado por meio de um ligante ao oligonucleotídeo, o peptídeo incluindo pelo menos um domínio catiônico compreendendo pelo menos 4 resíduos de aminoácidos e pelo menos um domínio hidrofóbico compreendendo pelo menos 3 resíduos de aminoácidos, desde que o peptídeo inclua um total de 7 a 40 resíduos de aminoácidos e não inclua quaisquer resíduos de aminoácidos artificiais; e o oligonucleotídeo incluindo um total de 12 a 40 nucleobases contíguas, onde pelo menos 12 nucleobases contíguas são complementares a uma sequência alvo em um gene da distrofina humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2021/050357 WO2022171972A1 (en) | 2021-02-12 | 2021-02-12 | Cell-penetrating peptide conjugates and methods of their use |
PCT/GB2022/050371 WO2022172019A1 (en) | 2021-02-12 | 2022-02-11 | Cell-penetrating peptide conjugates and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023016183A2 true BR112023016183A2 (pt) | 2023-12-12 |
Family
ID=74669201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023016183A BR112023016183A2 (pt) | 2021-02-12 | 2022-02-11 | Conjugados de peptídeo de penetração celular e métodos de uso dos mesmos |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4291244A1 (pt) |
JP (1) | JP2024506099A (pt) |
KR (1) | KR20240006019A (pt) |
CN (1) | CN117295525A (pt) |
AU (2) | AU2021427595A1 (pt) |
BR (1) | BR112023016183A2 (pt) |
CA (2) | CA3211038A1 (pt) |
IL (1) | IL305117A (pt) |
WO (2) | WO2022171972A1 (pt) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
EP2206781B1 (en) | 2004-06-28 | 2015-12-02 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
JP2011523557A (ja) * | 2008-06-04 | 2011-08-18 | メディカル リサーチ カウンシル | ペプチド |
BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
KR101958491B1 (ko) | 2009-11-12 | 2019-03-15 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
KR102339196B1 (ko) * | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
WO2019067981A1 (en) * | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
US20200254002A1 (en) * | 2017-09-28 | 2020-08-13 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
WO2019067975A1 (en) * | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
KR20210109551A (ko) | 2018-12-07 | 2021-09-06 | 옥스포드 유니버시티 이노베이션 리미티드 | 링커 |
WO2020214763A1 (en) * | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
WO2020257489A1 (en) * | 2019-06-19 | 2020-12-24 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
-
2021
- 2021-02-12 AU AU2021427595A patent/AU2021427595A1/en active Pending
- 2021-02-12 WO PCT/GB2021/050357 patent/WO2022171972A1/en active Application Filing
- 2021-02-12 CA CA3211038A patent/CA3211038A1/en active Pending
-
2022
- 2022-02-11 BR BR112023016183A patent/BR112023016183A2/pt unknown
- 2022-02-11 KR KR1020237029218A patent/KR20240006019A/ko unknown
- 2022-02-11 CA CA3211042A patent/CA3211042A1/en active Pending
- 2022-02-11 WO PCT/GB2022/050371 patent/WO2022172019A1/en active Application Filing
- 2022-02-11 EP EP22704422.9A patent/EP4291244A1/en active Pending
- 2022-02-11 IL IL305117A patent/IL305117A/en unknown
- 2022-02-11 CN CN202280028220.8A patent/CN117295525A/zh active Pending
- 2022-02-11 JP JP2023548577A patent/JP2024506099A/ja active Pending
- 2022-02-11 AU AU2022220252A patent/AU2022220252A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4291244A1 (en) | 2023-12-20 |
CA3211038A1 (en) | 2022-08-18 |
CA3211042A1 (en) | 2022-08-18 |
JP2024506099A (ja) | 2024-02-08 |
WO2022172019A1 (en) | 2022-08-18 |
AU2021427595A1 (en) | 2023-09-28 |
AU2022220252A1 (en) | 2023-09-28 |
WO2022171972A1 (en) | 2022-08-18 |
CN117295525A (zh) | 2023-12-26 |
KR20240006019A (ko) | 2024-01-12 |
IL305117A (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Programmable protein–DNA hybrid hydrogels for the immobilization and release of functional proteins | |
CY1113370T1 (el) | Ενεσιμο φαρμακευτικο σκευασμα αποτελουμενο απο ενα κυτταροστατικο και μια μηλεϊνιμιδο ομαδα συνδεομενη δια ενος παρεμβαλλομενου μοριου | |
Bessonov et al. | Characterization of purified human Bact spliceosomal complexes reveals compositional and morphological changes during spliceosome activation and first step catalysis | |
CN116115629A (zh) | 核酸产品及其施用方法 | |
Korzhnev et al. | Targeting the translesion synthesis pathway for the development of anti-cancer chemotherapeutics | |
DE602006020617D1 (de) | Lactoferrin-peptide, geeignet als in die zelle eindringende peptide | |
WO2007047301A3 (en) | Selective posttranslational modification of phage-displayed polypeptides | |
HUP9700428A2 (hu) | Célsejtspecifikus vektorok gének beépítésére, a vektorokat tartalmazó gyógyászati készítmények és azok alkalmazása | |
ATE335848T1 (de) | Verankerte strangverdrängungsverstärkung auf einem elektronisch adressierbaren microchip | |
BRPI0412845A (pt) | herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo | |
BRPI0415622B8 (pt) | uso de uma linhagem de células de somito ou retina de pato imortalizada, bem como métodos para preparar uma linhagem de células de somito ou retina de pato imortalizada, e para produção de vírus | |
CY1109744T1 (el) | Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων | |
DE69840216D1 (de) | Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden | |
WO2007133682A3 (en) | 100% sequence identity detection methods for variable genomes | |
WO2009101518A3 (en) | Gellan gum based hydrogels for regenerative medicine and tissue engineering applications, its system, and processing devices | |
BR9909745A (pt) | Peptìdeo, peptìdeo de fusão, medicamento, composição, fragmento de ácido nucléico, gene quimérico, vetor de clonagem ou de expressão para a transformação de um organismo hospedeiro, organismos hospedeiros transformados, célula vegetal transformada, planta transformada e sua semente, processo de transformação dos organismo hospedeiros, processo de cultura das plantas transformadas e processo de preparação de heliomicida | |
BR112021019701A2 (pt) | Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos | |
Shiraishi et al. | Improved cellular uptake of antisense peptide nucleic acids by conjugation to a cell-penetrating peptide and a lipid domain | |
CA3193961A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
Yakovlev et al. | Molecular partners of Cortexin in the brain | |
BR112023016183A2 (pt) | Conjugados de peptídeo de penetração celular e métodos de uso dos mesmos | |
BR0010537A (pt) | Método para triar indivìduos de teste para identificar aqueles tendo mais provavelmente melhores traços de crescimento, desenvolvimento, reprodução e esqueleto, tais como taxas de ganho, comprimento de esqueleto ou tamanho de ninhada e para identificar um marcador genético para taxa de crescimento de porco, comprimento de esqueleto, tamanho de ninhada ou infeção de varrão, kit para avaliar uma amostra de dna de suìno, iniciador para ensaiar quanto a presença de um sìtio sph1 polìmero do gene cyp11a1 de suìno, marcador genético associado com a taxa de crescimento, sequência de dna de região não-traduzida 5'do gene cyp11a1 de suìno, iniciador projetado para amplificar um sìtio de restrição sph1 polimórfico do gene cyp11a1 de suìno e método para triar porco | |
Liu et al. | Phosphorylation of replication protein A by S-phase checkpoint kinases | |
Alzhanova et al. | Aminoacyl-tRNA synthetases of rabbit reticulocytes with and without the ability to bind high-Mr RNA | |
EA201892239A1 (ru) | Материал на основе полимера, имеющий ковалентно связанные ферментативно деградируемые пептидные последовательности |